# A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

> **NCT03844256** · PHASE1,PHASE2 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 50 (estimated)

## Conditions studied

- Urinary Bladder Cancer
- Invasive Bladder Cancer

## Interventions

- **COMBINATION_PRODUCT:** nivolumab 480mg
- **COMBINATION_PRODUCT:** nivolumab 3mg/kg, ipilimumab 1mg/kg
- **COMBINATION_PRODUCT:** nivolumab 1mg/kg, ipilimumab 3mg/kg

## Key facts

- **NCT ID:** NCT03844256
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-07
- **Primary completion:** 2024-07
- **Final completion:** 2026-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844256, "A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03844256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*